Status:
COMPLETED
Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose is to assess the response of add-on therapy, based on CGI-I scale, at 4 weeks, in patients with MDD who had an inadequate disease control with antidepressant medication.
Detailed Description
A cross-sectional observational study to describe treatment management of patients with Major Depressive Disorder (MDD) and inadequate response to antidepressants in Greece
Eligibility Criteria
Inclusion
- Diagnosis of MDD as per DSM-IV
- Patients with an inadequate disease control during antidepressant therapy
- Patients who already receive add-on therapy and have completed 4-5 weeks of treatment at the time of their enrolment in the study.
Exclusion
- Patients fulfilling criteria for diagnosis of any other psychiatric condition (except for MDD), as per DSM-IV Axis I,
- Concomitant organic mental disorder or mental retardation Substance abuse or dependence (with the exception of nicotine dependence), as defined by DSM-IV criteria Participation in another study
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
545 Patients enrolled
Trial Details
Trial ID
NCT01397903
Start Date
September 1 2011
End Date
March 1 2012
Last Update
June 25 2012
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Arta, Artas, Greece
2
Research Site
Athens, Attica, Greece
3
Research Site
Chaïdári, Attica, Greece
4
Research Site
Dafni, Attica, Greece